CClinicalTrials.gg
CompletedNCT03114267Etude thyrovirUpdated Apr 14, 2017

Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis

An observational study in Autoimmune Diseases and Chronic Lymphocytic Thyroiditis, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
64
Ages
18 Years and older
Sex
All
01

Study summary

Autoimmune diseases represent a heterogeneous group of pathologies whose etiopathogenic mechanisms are most often unknown. Autoimmune diseases are the leading cause of morbidity and mortality in young women and autoimmune thyroid diseases are the most common.

Viral infections are the main environmental factors suspected of triggering autoimmune diseases. Several viruses are certainly involved, all of which are possibly capable of triggering an autoimmune response. However, the precise identification of the viruses involved remains to be established.

It has been shown for the first time by the 2005 PHRC that enteroviral RNA is present in perioperative specimens of thyroid tissue. However, this case-control study did not show any difference between the thyroid group and the group other thyroid pathologies It has been recently published that Parvovirus is possibly involved in thyroiditis: the parvoviral genome is present in the thyroid tissue of Hashimoto thyroiditis operated and more precisely is present within the thyrocytes itself.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients were recruited after PHRC 2005. Written information for the extension of the study will be sent with a copy of the summary of the scientific publication on Enterovirus (PHRC 2005).

Inclusion criteria

  • Patients participating in PHRC 2005 "involvement of enteroviruses in TLC pathogenesis"
  • Inclusion of TLC: presence of a significant lymphocyte infiltrate within the thyroid parenchyma defined by the presence of clusters of more than 30 to 50 lymphocytes
  • Inclusion of controls: absence of significant lymphocyte infiltrate

Exclusion criteria

Exclusion Criteria:

  • Persons refusing to participate in research
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
64 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient with chronic lymphocytic thyroiditis

    Other: Comparison of the prevalences of the parvovirus genome

  • Healthy subjects

    Other: Comparison of the prevalences of the parvovirus genome

Interventions

  • OtherComparison of the prevalences of the parvovirus genome

    Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature

05

What researchers measure

Primary outcomes

  1. Analysis of the viral genome by PCR carried out in the Virology department, Analysis of the presence of capsid protein

    Time frame: 1 day

06

Study locations

1 site
  • CHU Amiens Picardie
    Amiens, Picardie 80054, France
07

Registry details

Key details

Study ID
NCT03114267
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Apr 14, 2017
Start date
Jan 6, 2012
Primary completion
Jan 6, 2015
Completion
Jan 6, 2015
Last update
Apr 14, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion